FlaviTech

Low cost and fast diagnostics for mosquito-borne illness

WHAT WE DO

From Zika to Dengue, mosquito-born illnesses are growing in developing and developed countries. FlaviTech detects diseases earlier by developing and commercializing the use of antibodies against non-structural viral proteins, eliminating cross-reactivity between viruses.

Japanese Encephalitis
Zika
Tick-borne Encephalitis
Dengue
West Nile
Yellow Fever



100+ Million
infections per year, globally

MARKET SIZE

The market for infectious disease testing is expected to grow from $16.8 billion in 2015 to $20.9 billion in 2020.

OTHER KEY PLAYERS

Roche · CHEMBIO DIAGNOSTIC SYSTEMS, INC. · biocan · LabCorp · Quest Diagnostics · AT FIRST

PROGRESS & MILESTONES

- Developed prototype zika virus detection system called the multiplex microsphere immunoassay (MIA); conditionally approved for patient sample tests in New York State
- Proof-of-concept of reporter virus neutralization assay; ready for clinical use; provisional patent filed; publication pending
- Partnership with Galveston National Laboratory and Brazilian government
- Validation testing planned in Brazil and neighboring countries

TARGET CUSTOMER PAIN POINTS

- Globally women in their child bearing years fear the possibility of birthing a microcephalic child
- Hospitals, clinics, primary care and OB/GYN offices need solutions for faster diagnosis of infection and disease
- Research and academic institutions need better solutions for human and animal testing to aid in developing vaccines and treatments

THE PRODUCTS

1. [PROTOTYPE] Non-structural protein assay with diagnostic algorithm
2. [IDEATION] At home test kits (lateral flow devices), in-field test kits (mobile detection), point-of-care testing kits and instrumentation, and testing services and interpretative analysis
3. [PROVISIONAL PATENT] Reporter virus neutralization assay

DIFFERENTIATION

- Assay turnaround time less than 48 hrs (CDC turnaround measured in wks)
- No cross-reactivity across viruses
- Laser-focus on each end-user's experience not only innovating the science

MANAGEMENT TEAM

Pei-Yong Shi, PhD ♦ Alexander Vo, PhD ♦ Ryan Westberry, MS, MBA